Welcome to the e-CCO Library!

P606: Intestinal fatty acid binding protein parallels temporal changes in Harvey-Bradshaw Index and TNFα in response to infliximab in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hellström P.M., Al-Saffar K.A., Tartera Diaz H., Ram G.V., Webb D.-L.

Created: Wednesday, 20 February 2019, 10:36 AM
P606: Significant regional differences in referral patterns for bowel resection in Crohn's disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Iesalnieks, I.(1)*;Adamou, A.(2);Magdalena, B.(2);Streetz, K.(3);
Created: Friday, 14 July 2023, 11:05 AM
P606: Steroid use in inflammatory bowel disease patients on biological therapy in Montenegro
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Smolovic*1, M. Lukic1, O. Sekulic1, D. Muhovic1, V. Milosevic2, B. Vukcevic3

Created: Friday, 22 February 2019, 9:41 AM
P606: Use of TNF-α-antagonists and systemic steroids is associated with attenuated immunogenicity against SARS-CoV-2 in fully vaccinated patients with Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Otten , A.T.(1);Bourgonje , A.R.(1);Horinga , P.P.(1);van der Meulen , H.H.(1);van Leer-Buter , C.C.(2);Dijkstra , G.(1);Visschedijk , M.C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P607 Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Schultz1, I. Diakite2, J. Carter2, S. Snedecor2, R. Turpin3

Created: Thursday, 30 January 2020, 10:12 AM
P607: Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Fischer1*, E. Klenske1, H. Schmitt1, F. Vitali1, S. Hirschmann1, F. Koch1, A. Ramming2, S. Zundler1, D. Nagore3, W. Uter4, M.F. Neurath1, R. Atreya1

Created: Thursday, 21 February 2019, 9:14 AM
P607: Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open
Year: 2022
Source: ECCO'22
Authors: Rubin , D.T.(1);Vavricka , S.R.(2);Armuzzi , A.(3);Dubinsky , M.C.(4);Sharara , A.I.(5);Modesto , I.(6);Fellmann , M.(7);Liguori , G.(8);Lawendy , N.(9);Cadatal , M.J.(10);Lichtenstein , G.R.(11);
Created: Friday, 11 February 2022, 3:56 PM
P607: Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Narula1, B. Lauzon*1, J. Marshall1

Created: Friday, 22 February 2019, 9:41 AM
P607: HLA-DQA1*05 Allele Carriage and Anti-TNF Therapy Persistence in Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Doherty, J.(1)*;Ryan, A.(2);Quinn, E.(2);Dolan, J.(2);Corcoran, R.(3);O' Hara, F.(4);Bailey, Y.(4);McNamara, D.(4);Doherty, G.(5);Kevans, D.(3);
Created: Friday, 14 July 2023, 11:05 AM
P607: Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989–2013): a multicenter nationwide study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ordas I.*1, Domenech E.2, Aguas M.3, Fernandez-Bañares F.4, García S.5, Peñalva M.6, Muñoz C.7, García-Sánchez V.8, Llaό J.9, Jiménez C.E.10, Merino O.11, Gomollόn F.12, Piqueras M.13, Vera M.14, Márquez L.15, De Castro M.16, Gutiérrez A.17, Cabriada J.L.18, Alcaide N.19, Calvet X.20, Montoro M.A.21, Arias L.22, Panés J.1, Esteve M.4

Created: Wednesday, 20 February 2019, 10:36 AM
P607: The Faroese IBD Study: Update on incidence from 2015-2020 and prevalence from 1960-2020
Year: 2021
Source: ECCO'21 Virtual
Authors: Nielsen, K.R.(1);Midjord, J.(1);Hammer, T.(2);Lophaven, S.(3);Burisch, J.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P608 Endoscopic treatment of enterocutaneous fistulas in Crohn’s disease patient
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Yzet, J.P. Le Mouel, S. Hakim, F. Brazier, M. Fumery

Created: Thursday, 30 January 2020, 10:12 AM
P608: Crohn’s disease patients with high baseline symptoms achieve clinical remission more rapidly with Budesonide than with Mesalazine
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Kunz*1, R. Hofmann1

Created: Friday, 22 February 2019, 9:41 AM
P608: Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU
Year: 2021
Source: ECCO'21 Virtual
Authors: Zabana Abdo, Y.(1,2);Marín-Jiménez, I.(3);Rodríguez-Lago, I.(4);Ramírez Esteso, F.(5);Meijilde, S.(6);Ramos, L.(7);Gomollón, F.(2,8);Muñoz, F.(9);Suris, G.(10);Ortiz de Zárate, J.(11);Huguet, J.M.(12);Llaó, J.(13);García-Sepulcre, M.(14);Sierra, M.(15);Durà, M.(16);Estrecha, S.(17);Fuentes Coronel, A.(18);Hinojosa, E.(19);Olivan, L.(20);Iglesias, E.(21);Gutiérrez, A.(2,22);Varela, P.(23);Rull, N.(24);Gilabert, P.(25);Hernández-Camba, A.(26);Brotons, A.(27);Ginard, D.(28);Sesé, E.(29);Carpio, D.(30);Aceituno, M.(1,2);Cabriada, J.L.(4);González-Lama, Y.(31);Jiménez, L.(32);Chaparro, M.(2,33);López-San Román, A.(34);Alba, C.(35);Plaza-Santos, R.(36);Piqueras, M.(37);Domènech, E.(2,38);Esteve, M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P608: IV iron treatment of iron deficiency anaemia with ferumoxytol in patients with inflammatory bowel disease unable to take oral iron: A randomised controlled trial vs. ferric carboxymaltose
Year: 2018
Source: ECCO '18 Vienna
Authors:

W. Strauss*, N. Dahl, J. Jiang, K. Bernard, R. Kaper, J. Krop

Created: Thursday, 21 February 2019, 9:14 AM
P608: New anti-migration extractible metal stents for Crohn's disease strictures: a nationwide GETAID-SFED cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Attar A.*1, Branche J.2, Coron E.3, Privat J.4, Caillo L.5, Chevaux J.-B.6, Vuitton L.7, Amiot A.8, Belkhodja H.9, Buisson A.10, Dray X.11, Jerber L.12, Ponchon T.13, Bouhnik Y.1, Peyrin-Biroulet L.6

Created: Wednesday, 20 February 2019, 10:36 AM
P608: Systematic review: The impact and importance of body composition in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Ding, N.(1,2);Tassone, D.(1);Al Bakir, I.(2);Wu, K.(1);Connell, W.(1);Thompson, A.(1);Malietzis, G.(3);Lung, P.(2);Singh, S.(4);Choi, C.H.(2);Gabe, S.(2);Jenkins, J.(3);Hart, A.(2);
Created: Friday, 11 February 2022, 3:56 PM
P608: Time to onset of effect of biologics and small molecules in moderate-to-severe or acute severe ulcerative colitis – a systematic review and network meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Attauabi, M.(1,2)*;Dahl, E.K.(1);Burisch, J.(2,3);Gubatan, J.(4);Nielsen, O.H.(1);Seidelin, J.B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P609 An IBD dermatology multidisciplinary clinic: A single tertiary centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Levy1, H. Matz2, N. Maharshak3, A. Waizbard4

Created: Thursday, 30 January 2020, 10:12 AM
P609: A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Little R., Taylor K., Friedman A., Headon B., Gibson P., Sparrow M., Ward M.

Created: Wednesday, 20 February 2019, 10:36 AM